Type 1 Diabetes Mellitus, Autoimmune Disease
NKTRNektar TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Rezpegaldesleukin (NKTR-358) (Treg Stimulator) in Type 1 Diabetes Mellitus, Autoimmune Disease. The expected timing is based on the latest available company guidance and may change.
11/06/25:- Rezpegaldesleukin is being evaluated in an ongoing Phase 2 trial in type 1 diabetes mellitus; no data or timing guidance for future readouts has been provided. 03/12/26:- Initial data from TrialNet Phase 2 Type 1 diabetes study expected in 2027. 05/07/26:- Initial data from the TrialNet Phase 2 Type 1 diabetes study still expected in 2027. 08/13/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.